Autoantibodies in hepatitis C virus-related chronic liver disease

Hepatitis Monthly

Volumn 8, Issue 4, 2008, Pages 295-303

  Himoto, Takashi ^a   Nishioka, Mikio ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Antiviral treatment; Autoantibodies; Hepatitis C virus; HLA haplotype; Molecular mimicry

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIVIRUS AGENT; AUTOANTIBODY; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; CORTICOSTEROID; ENDOTHELIAL CELL ANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIBODY; HLA ANTIGEN; INSULIN ANTIBODY; INTERFERON; LA ANTIBODY; MICROSOME ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PANCREAS ISLET CELL ANTIBODY; PARIETAL CELL ANTIBODY; PEGINTERFERON; RHEUMATOID FACTOR; RIBAVIRIN; RO ANTIBODY; SMOOTH MUSCLE ANTIBODY; THROMBOCYTE ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHRONIC LIVER DISEASE; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG RESPONSE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR MIMICRY; MONOTHERAPY; PROGNOSIS; REVIEW;

EID: 67649212367     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Garzelli C, Pacciardi A, Basolo F, Falcone G. Mechanisms other than polyclonal B cell activation possibly involved in Epstein-Barr virus-induced autoimmunity. Clin Exp Immunol. 1989; 76(3):412-6.
2. Fujinami RS, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A. 1983; 80(8):2346-50.
3. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun. 2008;30(1-2):5-11.
4. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19(4):841-8.
5. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol. 1999;31 Suppl 1:39-42.
6. Zauli D, Cassani F, Bianchi FB. Auto-antibodies in hepatitis C. Biomed Pharmacother. 1999;53(5-6):234-41.
7. Himoto T, Nishioka M. Current trends of autoantibodies in liver diseases. Current Trends in Immunology. 2008;9:33-42.
8. Bogdanos DP, Mieli-Vergani G, Vergani D. Non-organspecific autoantibodies in hepatitis C virus infection: do they matter? Clin Infect Dis. 2005;40(4):508-10.
9. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997;26(3):561-6.
10. Zein NN, Persing DH, Czaja AJ. Viral genotypes as determinants of autoimmune expression in chronic hepatitis C. Mayo Clin Proc. 1999;74(5):454-60.
11. Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut. 1999;45(3):435-41.
12. Peng YC, Hsieh SC, Yang DY, et al. Expression and clinical significance of antinuclear antibody in hepatitis C virus infection. J Clin Gastroenterol. 2001;33(5):402-6.
13. Bogdanos DP, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences. Liver. 2001;21(4):225-32.
14. Gregorio GV, Choudhuri K, Ma Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol. 2003;133(3):404-13.
15. Muro Y, Azuma N, Onouchi H, et al. Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3. Clin Exp Immunol. 2000; 120(1):218-23.
16. Ramos-Casals M, De Vita S, Tzioufas AG. Hepatitis C virus, Sjogren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer. Autoimmun Rev. 2005;4(1):8-15.
17. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282(5390):938-41.
18. Sene D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation - the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford). 2007; 46(1):65-9.
19. Toubi E, Gordon S, Kessel A, et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006; 27(2):134-9.
20. Luo JC, Hwang SJ, Li CP, et al. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol. 1998;13(5):475-9.
21. Giannini E, Botta F, Fasoli A, et al. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Dig Dis Sci. 2001;46(3):524-9.
22. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26(2):459-66.
23. Bianchi FB, Muratori P, Granito A, Pappas G, Ferri S, Muratori L. Hepatitis C and autoreactivity. Dig Liver Dis. 2007;39 Suppl 1:S22-4.
24. Nishioka M, Morshed SA, Kono K, et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol. 1997;26(5):992-1000.
25. Nishioka M, Morshed SA, Parveen S, Kono K, Matsuoka H, Manns MP. Antibodies to P450IID6, SLA, PDH-E2 and BCKD-E2 in Japanese patients with chronic hepatitis. J Gastroenterol Hepatol. 1997; 12(12):862-8.
26. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology. 1987; 7(6):1333-9.
27. Muratori L, Bogdanos DP, Muratori P, et al. Susceptibility to thyroid disorders in hepatitis C. Clin Gastroenterol Hepatol. 2005;3(6):595-603.
28. Lenzi M, Manotti P, Muratori L, et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut. 1995;36(5):749-54.
29. Rigopoulou EI, Mytilinaiou M, Romanidou O, Liaskos C, Dalekos GN. Autoimmune hepatitis-specific antibodies against soluble liver antigen and liver cytosol type 1 in patients with chronic viral hepatitis. J Autoimmune Dis. 2007;4:2.
30. Vitozzi S, Lapierre P, Djilali-Saiah I, Marceau G, Beland K, Alvarez F. Anti-soluble liver antigen (SLA) antibodies in chronic HCV infection. Autoimmunity. 2004;37(3):217-22.
31. Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun. 2003;21(1):77-82.
32. Husa P, Chalupa P, Stroblova H, Husova L, Slesinger P, Zajic J. Autoantibodies to asialoglycoprotein receptor in chronic hepatitis C patients. Acta Virol. 2001;45(1):7-11.
33. Treichel U, Gerken G, Rossol S, Rotthauwe HW, Meyer zum Buschenfelde KH, Poralla T. Autoantibodies against the human asialoglycoprotein receptor: effects of therapy in autoimmune and virus-induced chronic active hepatitis. J Hepatol. 1993;19(1):55-63.
34. Saadoun D, Sadallah S, Trendelenburg M, et al. Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol. 2006; 145(2):308-12.
35. Grimbert S, Johanet C, Bendjaballah F, Homberg JC, Poupon R, Beaugrand M. Antimitochondrial antibodies in patients with chronic hepatitis C. Liver. 1996;16(3):161-5.
36. Tanaka H, Maeda T, Onishi S, Yamamoto Y. Humoral and cellular immune responses to dihydrolipoamide dehydrogenase (E3): lack of specificity for primary biliary cirrhosis. Liver. 1995;15(3):121-5.
37. Wu YY, Hsu TC, Chen TY, et al. Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol. 2002;128(2):347-52.
38. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995;108(1):157-64.
39. Muratori P, Czaja AJ, Muratori L, et al. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C. Dig Dis Sci. 2007; 52(1):179-84.
40. Miyakawa H, Kitazawa E, Abe K, et al. Chronic hepatitis C associated with anti-liver/kidney microsome-1 antibody is not a subgroup of autoimmune hepatitis. J Gastroenterol. 1997; 32(6):769-76.
41. Seki T, Kiyosawa K, Inoko H, Ota M. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology. 1990; 12(6):1300-4.
42. Bogdanos DP, Lenzi M, Okamoto M, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol. 2004; 17(1):83-92.
43. Smyth CM, McKiernan SM, Hagan R, et al. Chronic hepatitis C infection and sicca syndrome: a clear association with HLA DQB1*02. Eur J Gastroenterol Hepatol. 2007;19(6):493-8.
44. Wu CS, Hu CY, Hsu PN. Anti-SSB/La antibody is negatively associated with HLA-DR2 in chronic hepatitis C infection. Clin Rheumatol. 2008; 27(3):365-8.
45. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M. HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. J Hepatol. 1999;30(5):794-800.
46. Labbadia G, Martocchia A, Mammarella A, et al. Association between human leukocyte antigen (HLA) and interferon- induced thyroid diseases in four patients with HCV-related chronic hepatitis. Neuro Endocrinol Lett. 2005;26(2):109-12.
47. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune Type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med. 2001;18(4):329-32.
48. Sthoeger ZM, Fogel M, Smirov A, et al. Anticardiolipin autoantibodies in serum samples and cryoglobulins of patients with chronic hepatitis C infection. Ann Rheum Dis. 2000; 59(6):483-6.
49. Cojocaru IM, Cojocaru M, Iacob SA. High prevalence of anticardiolipin antibodies in patients with asymptomatic hepatitis C virus infection associated acute ischemic stroke. Rom J Intern Med. 2005; 43(1-2):89-95.
50. Nagao Y, Tsubone K, Kimura R, et al. High prevalence of anticardiolipin antibodies in patients with HCV-associated oral lichen planus. Int J Mol Med. 2002;9(3):293-7.
51. Carrozzo M, Gandolfo S, Lodi G, et al. Oral lichen planus in patients infected or noninfected with hepatitis C virus: the role of autoimmunity. J Oral Pathol Med. 1999;28(1):16-9.
52. Jorgensen C, Legouffe MC, Perney P, et al. Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum. 1996;39(7):1166-71.
53. Ramos-Casals M, Font J, Garcia-Carrasco M, et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum. 2000; 43(12):2801-6.
54. Ramos-Casals M, la Civita L, de Vita S, et al. Characterization of B cell lymphoma in patients with Sjogren's syndrome and hepatitis C virus infection. Arthritis Rheum. 2007;57(1):161-70.
55. Ganne-Carrie N, Medini A, Coderc E, et al. Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study. J Autoimmun. 2000;14(2):189-93.
56. Kee KM, Lee CM, Wang JH, et al. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroenterol Hepatol. 2006;21(1 Pt 2):319-26.
57. Ramos-Casals M, Pares A, Jara LJ, et al. Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. J Viral Hepat. 2005;12(6):648-54.
58. Himoto T, Kuriyama S, Zhang JY, et al. Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol. 2005;27(4):1079-85.
59. Himoto T, Kuriyama S, Zhang JY, Chan EK, Nishioka M, Tan EM. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol. 2005;26(2):311-7.
60. Mozo L, Simo A, Suarez A, Rodrigo L, Gutierrez C. Autoantibodies to Golgi proteins in hepatocellular carcinoma: case report and literature review. Eur J Gastroenterol Hepatol. 2002;14(7):771-4.
61. Fried MW, Draguesku JO, Shindo M, et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci. 1993;38(4):631-6.
62. Noda K, Enomoto N, Arai K, et al. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol. 1996;31(7):716-22.
63. Iijima Y, Kato T, Miyakawa H, et al. Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type 1. J Gastroenterol Hepatol. 2001; 16(7):782-8.
64. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology. 1995;22(5):1374-8.
65. Gatselis NK, Georgiadou SP, Koukoulis GK, et al. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther. 2006;24(11-12):1563-73.
66. Carella C, Mazziotti G, Morisco F, et al. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002;146(6):743-9.
67. Calleja JL, Albillos A, Cacho G, Iborra J, Abreu L, Escartin P. Interferon and prednisone therapy in chronic hepatitis C with non-organ-specific antibodies. J Hepatol. 1996; 24(3):308-12.
68. Petersen-Benz C, Kasper HU, Dries V, Goeser T. Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis C-autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol. 2004;2(5):440-3.
69. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993; 18(3):342-52.
70. Meyer zum Buschenfelde KH, Lohse AW, Gerken G, et al. The role of autoimmunity in hepatitis C infection. J Hepatol. 1995;22(1 Suppl):93-6.
71. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;21(3):613-9.
72. Muratori P, Muratori L, Guidi M, et al. Clinical impact of non-organ-specific autoantibodies on the response to combined antiviral treatment in patients with hepatitis C. Clin Infect Dis. 2005; 40(4):501-7.
73. Gatselis NK, Georgiadou SP, Tassopoulos N, et al. Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: a pilot study. World J Gastroenterol. 2005;11(4):482-7.
74. von Mühlen CA, Chan EK, Peebles CL, Imai H, Kiyosawa K, Tan EM. Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases. Clin Exp Immunol. 1995;100(1):67-74.
75. Wasmuth HE, Stolte C, Geier A, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis. 2004;4:4.
76. Beland K, Lapierre P, Marceau G, Alvarez F. Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection. J Autoimmun. 2004;22(2):159-66.
77. Warny M, Brenard R, Cornu C, Tomasi JP, Geubel AP. Anti-neutrophil antibodies in chronic hepatitis and the effect of alpha-interferon therapy. J Hepatol. 1993;17(3):294-300.
78. Betterle C, Fabris P, Zanchetta R, et al. Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care. 2000;23(8):1177-81.
79. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 1993; 18(2):253-7.
80. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1994; 89(3):399-403.
81. Huang MJ, Tsai SL, Huang BY, Sheen IS, Yeh CT, Liaw YF. Prevalence and significance of thyroid autoantibodies in patients with chronic hepatitis C virus infection: a prospective controlled study. Clin Endocrinol (Oxf). 1999;50(4):503-9.
82. Huang JF, Chuang WL, Dai CY, et al. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. J Viral Hepat. 2006;13(6):396-401.
83. Floreani A, Betterle C, Carderi I, et al. Is hepatitis C virus a risk factor for thyroid autoimmunity? J Viral Hepat. 2006; 13(4):272-7.
84. Nduwayo L, Bacq Y, Valat C, Goudeau A, Lecomte P. [Thyroid function and autoimmunity in 215 patients seropositive for the hepatitis C virus]. Ann Endocrinol (Paris). 1998;59(1):9-13.
85. Dalgard O, Bjoro K, Hellum K, et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251(5):400-6.
86. Sene D, Ghillani-Dalbin P, Limal N, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjogren's syndrome. Ann Rheum Dis. 2006;65(3):394-7.
87. D'Amico E, Palazzi C, Cacciatore P, et al. Anti-ENA antibodies in patients with chronic hepatitis C virus infection. Dig Dis Sci. 2002;47(4):755-9.
88. Valentini G, Mantelli A, Persico M, et al. Serological and clinical markers of autoimmune disease in HCV-infected subjects with different disease conditions. Clin Exp Rheumatol. 1999; 17(1):75-9.
89. Banks SE, Riley TR, 3rd, Naides SJ. Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis C and nonalcoholic fatty liver disease. Dig Dis Sci. 2007;52(5):1177-82.
90. Tzang BS, Chen TY, Hsu TC, Liu YC, Tsay GJ. Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection. Ann Rheum Dis. 1999;58(10):630-4.
91. Hsu TC, Tsay GJ, Chen TY, Liu YC, Tzang BS. Anti-PCNA autoantibodies preferentially recognize C-terminal of PCNA in patients with chronic hepatitis B virus infection. Clin Exp Immunol. 2006; 144(1):110-6.
92. Bombardieri M, Alessandri C, Labbadia G, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther. 2004;6(2):R137-41.
93. Koga T, Migita K, Miyashita T, et al. Determination of anticyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol. 2008;26(1):121-4.
94. Riccio A, Postiglione L, La Dogana P, Spano A, Marzocchella C, Tarantino G. Anti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis. J Biol Regul Homeost Agents. 2008; 22(1):57-61.
95. Buskila D, Shnaider A, Neumann L, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum. 1998;28(2):107-13.
96. Prieto J, Yuste JR, Beloqui O, et al. Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology. 1996; 23(2):199-204.
97. Liaskos C, Rigopoulou E, Zachou K, et al. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun. 2005;24(3):251-60.
98. Lienesch DW, Sherman KE, Metzger A, Shen GQ. Anti-Clq antibodies in patients with chronic hepatitis C infection. Clin Exp Rheumatol. 2006;24(2):183-5.
99. Cacoub P, Ghillani P, Revelen R, et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol. 1999;31(4):598-603.
100. Kessenbrock K, Fritzler MJ, Groves M, et al. Diverse humoral autoimmunity to the ribosomal P proteins in systemic lupus erythematosus and hepatitis C virus infection. J Mol Med. 2007; 85(9):953-9.
101. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut. 2001; 48(3):378-83.
102. Piquer S, Hernandez C, Enriquez J, et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med. 2001; 137(1):38-42.
103. di Cesare E, Previti M, Russo F, et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci. 1996;41(8):1672-7.
104. Raedle J, Roth WK, Oremek G, Caspary WF, Zeuzem S. Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sci. 1995;40(12):2587-94.
105. Yagihashi A, Asanuma K, Kobayashi D, et al. Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity. 2005;38(6):445-8.
106. Parana R, Schinoni MI, de Freitas LA, et al. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C. Liver Int. 2006;26(9):1148-54.
107. Hernandez F, Blanquer A, Linares M, Lopez A, Tarin F, Cervero A. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol. 1998;99(4):217-20.
108. Panzer S, Seel E, Brunner M, et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol. 2006;77(6):513-7.
109. El Aggan HA, Sidkey F, El Gezery DA, Ghoneim E. Circulating anti-HLA antibodies in patients with chronic hepatitis C: relation to disease activity. Egypt J Immunol. 2004;11(2):71-9.